In an article entitled "Serving Up Data At Bio-IT World" in Chemical & Engineering News (C&E News) by Rick Mullen, the tranSMART Foundation and its Platform were mentioned. Dr. Rudy Potenzone, VP of Marketing for the Foundation, was interviewed.See the full article at: http://cen.acs.org/articles/93/i19/Serving-Data-BioWorld.html
R&D Magazine released its list of Finalists for the 53rd annual R&D 100 Awards, which honor the 100 most innovative technologies and services of the past year. The Press Release is available. Since 1963, the R&D 100 Awards have identified revolutionary technologies newly introduced to the market. Widely recognized as the “Oscars of Invention,” the R&D 100 Awards identify and celebrate the top technology products of the year. The tranSMART Platform v1.2 was named a finalist in the Software/Services category. This year’s Winners will be presented with their honors at the annual black-tie awards dinner on November 13, 2015 at Caesars Palace, Las Vegas, Nevada as part of its 2015 R&D 100 Awards & Technology Conference on November 12-13, 2015. The full list of Finalists is available.
San Diego, CA – June 16th, 2015 – Rancho BioSciences, The Data Curation Company, announced it has donated GWAS (Genome Wide Association Studies) ETL (Extract, Transform and Load) scripts and documentation for tranSMART v 1.2 Oracle to Github. Rancho worked in collaboration with two major pharmaceutical companies to make this happen. A script was developed for the latest version of tranSMART which performs indexing for the improved performance of the Genome Wide Association Visual Analyzer (GWAVA), tranSMART’s interactive Manhattan plotter developed by Peter Henstock of Pfizer. With the new scripts, Rancho improved the speed of the search queries so that tranSMART users can quickly and easily get the information they need. See FULL PRESS RELEASE
In an article in the EMR & EHR Newsletter, Andy Oram, an editor at O'Reilly Media, reviews the evolution of the tranSMART Foundation. As part of his coverage of the awards given to the Foundation and members of its community at BioIT World , Oram interviewed tranSMART CEO Keith Elliston. The articles reviews the rapid rise of the Foundation, the elements of its success, as well as reflecting on the challenges of the future. READ the entire article.
Bio-IT World Staff have posted an article on the Best Practice Award given to the Michael J Fox Foundation for its work with Thomson Reuters and the tranSMART Foundation. The article interviews Ken Kubota, Director of Data Science, and Keith Elliston and Rudy Potenzone from the tranSMART Foundation. http://www.bio-itworld.com/2015/5/15/michael-j-fox-foundation-brings-parkinsons-data-transmart.html
The tranSMART Foundation was awarded the Best in Show - Informatics by the judges at the BioIT World 2015 Conference taking place in Boston MA. The tranSMART Foundation was awarded a Best in Show Award for Informatics Tools & Data for its Open Source tranSMART Platform v1.2. The Michael J Fox Foundation was awarded a special Judges Prize Best Practice Award for its work, in cooperation with Thomson Reuters, in using the tranSMART Platform to load research data for its network of scientists. A poster presented by Ward Weistra also won an award for the collaboration of the Hyve with CTMM on the TraIT project, entitled "Multi-omics analysis in tranSMART using the Cell Line User Case dataset". For more on tranSMART at BioIT World 2015, and to access our Community Webinar recordings and various presentation decks, go to our BioIT World 2015 page.
The tranSMART Foundation announces its annual Community Meeting during the BioIT World Conference on the evening of April 22nd. Come join us for an evening of information exchange, updates and discussion around the Foundation and the evolution of our Platform. The Event is being hosted by ConvergeHEALTH by Deloitte, at the Deloitte offices in Boston. Please register if you intend to join us for this exciting event!
January 14, 2015 – The tranSMART Foundation, a non-profit organization providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, today announced that 20 life sciences and technology organizations have made substantial commitments by joining its Membership Program. Members not only become integral parts of the Foundation’s community, they also provide the financial support necessary to sustain the organization and continually enhance the tranSMART open-source platform. The benefits of membership include participation in sustaining the tranSMART open-source community, the opportunity to serve on the board of directors and membership on the 3C operating committees (Code, Content and Community). The work of the Foundation is directed by the board and carried out by the 3C Committees, their component Working Groups and the Foundation management team. “Since launching the Membership Program one year ago, we have had tremendous support from pharmaceutical, biotech and technology companies, as well as academic institutions who have become engaged in our efforts,” said tranSMART Foundation CEO Keith Elliston, PhD. “These organizations realize the value that the tranSMART open-source platform can offer to the advancement of translational medicine research, and the role of the tranSMART Foundation in catalyzing this community. We appreciate the dedication and support of all of our members, who have helped us mobilize the community to produce two new versions of the platform over the past 18 months, and we look forward to their continued contributions to propel this initiative forward.” The tranSMART Foundation is launching a new membership campaign for 2015. During this time, it will encourage each of its current members to renew their memberships, and will bring new members to the Foundation at both the Gold and Silver levels. ConvergeHEALTH by Deloitte, Oracle, PerkinElmer, Pfizer, Roche, Sanofi, and Takeda have all joined at the Gold Level, which includes a minimum investment of $100,000 per year to fund the Foundation. Additionally, John’s Hopkins University and the University of Michigan have joined as academic Gold members. At this level, these organizations can elect a representative from their company to the tranSMART board of directors and have a representative on all three of the Foundation’s 3C operating committees, focusing on Code, Community and Content. Silver-level members include: ARLION; AssureRx; Cognizant; Institute for Systems Biology; One Mind; Saama Technologies, Inc.; and the Hyve. Each of the Silver members makes a minimum investment of $5,000 to $20,000 to help fund the Foundation’s operations. Silver members have the opportunity to submit a representative to a pool of candidates to be elected the Foundation’s board, and can nominate one individual to one of the Foundation’s 3C’s committees. The Foundation also has an Affiliate program, whose members provide sponsorship and support for its activities. The Affiliate members include: BT-GS, Elevada, Harvard University, and Rancho Biosciences. About The tranSMART Foundation The tranSMART Foundation is a non-profit organization that provides an open-source, cloud-based, data-sharing and analysis platform that enables scientists at universities, disease foundations, pharmaceutical companies, and government agencies around the world to share pre-competitive data in a way that saves money and time in translating research findings into new therapies and diagnostic tools. Founded to steward the tranSMART platform, the Foundation is headquartered in Wakefield, Massachusetts with Centers of Excellence in Ann Arbor, Mich.; London, England; Boston, Mass.; and Amsterdam, Netherlands. The tranSMART Foundation can also be found on the web at www.tranSMARTFoundation.org. CLICK HERE for a copy of the Press Release.
The tranSMART Platform v1.2.3 has been released in early January 2015. The demo version is available now at the usual link. For details on the changes and availability of VMs and source, please see the tranSMART Foundation wiki pages.
BioIT World, Oct 1 2014. By Bio-IT World Staff. The U-BIOPRED project began with a big goal: to understand the factors that define severe asthma cases, splitting the disease into meaningful subtypes that may let doctors form better prognoses and treatment strategies. Ultimately, the project hopes to discover biomarkers that could be used to quickly diagnose subtypes of asthma, or even lead to new therapies. To do that, researchers are combining data from longitudinal clinical studies of both adults and children, and animal, in vitro and in silico models of the disease. Under the U-BIOPRED banner, a battery of multi-omics technologies is producing an unprecedented wealth of data on the cellular changes that underlie severe asthma. BIOPRED, or Unbiased BIOmarkers in PREDiction of respiratory disease outcomes, is a project of the Innovative Medicines Initiative (IMI), the largest European public-private partnership in the field of medicine, with a specific goal of laying the groundwork for new pharmaceuticals. The IMI invested €20 million ($25.4 million) in U-BIOPRED, distributed to a consortium that includes 20 academic institutions, ten members of the commercial European Federation of Pharmaceutical Industries and Associations, six patient advocacy groups, and others. For the full article CLICK HERE